ECSP078058A - Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos - Google Patents
Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentosInfo
- Publication number
- ECSP078058A ECSP078058A EC2007008058A ECSP078058A ECSP078058A EC SP078058 A ECSP078058 A EC SP078058A EC 2007008058 A EC2007008058 A EC 2007008058A EC SP078058 A ECSP078058 A EC SP078058A EC SP078058 A ECSP078058 A EC SP078058A
- Authority
- EC
- Ecuador
- Prior art keywords
- glicinamids
- medicines
- preparation
- new substituted
- salts
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Objeto de la presente invención son nuevas glicinamidas sustituidas de la fórmula general (I) (I)en las cuales D, M, R3, R4 y R5 están definidos como en la memoria descriptiva, sus tautómeros, sus enantiómeros, sus diastereoisómeros, sus mezclas y sus sales, en particular sus sales fisiológicamente compatibles con ácidos o bases inorgánicos u orgánicos, los cuales presentan valiosas propiedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05014270 | 2005-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP078058A true ECSP078058A (es) | 2008-01-23 |
Family
ID=35907001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007008058A ECSP078058A (es) | 2005-06-30 | 2007-12-27 | Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20100216769A1 (es) |
| EP (1) | EP1899330B9 (es) |
| JP (1) | JP4768016B2 (es) |
| KR (1) | KR101321722B1 (es) |
| CN (1) | CN101213195B (es) |
| AR (1) | AR054627A1 (es) |
| AT (1) | ATE489381T1 (es) |
| AU (1) | AU2006265216B2 (es) |
| BR (1) | BRPI0612580A8 (es) |
| CA (1) | CA2613059C (es) |
| CY (1) | CY1111627T1 (es) |
| DE (1) | DE502006008392D1 (es) |
| DK (1) | DK1899330T3 (es) |
| EA (1) | EA015188B1 (es) |
| EC (1) | ECSP078058A (es) |
| ES (1) | ES2357029T3 (es) |
| HR (1) | HRP20110044T2 (es) |
| IL (1) | IL188323A (es) |
| MX (1) | MX2007016253A (es) |
| MY (1) | MY145883A (es) |
| NO (1) | NO340670B1 (es) |
| NZ (1) | NZ565440A (es) |
| PE (1) | PE20070171A1 (es) |
| PL (1) | PL1899330T3 (es) |
| PT (1) | PT1899330E (es) |
| RS (1) | RS51572B (es) |
| SG (1) | SG163540A1 (es) |
| SI (1) | SI1899330T1 (es) |
| TW (1) | TWI392495B (es) |
| UA (1) | UA94910C2 (es) |
| WO (1) | WO2007003536A1 (es) |
| ZA (1) | ZA200708525B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1799684B1 (en) | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| WO2008009125A1 (en) * | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| PE20081834A1 (es) * | 2006-12-31 | 2009-01-16 | Boehringer Ingelheim Int | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos |
| EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2009063028A2 (en) * | 2007-11-15 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Substituted amides, manufacturing and use thereof as medicaments |
| JP5562865B2 (ja) | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Trpv1のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| US7998952B2 (en) | 2008-12-05 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | Thiolactams and uses thereof |
| AU2010216632A1 (en) * | 2009-02-17 | 2011-08-04 | Msd K.K. | 1,4-benzodiazepin-2-on derivatives |
| WO2011123495A1 (en) | 2010-03-30 | 2011-10-06 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| EP2758075B1 (en) | 2011-09-20 | 2023-05-03 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| EP2934581B1 (en) | 2012-12-18 | 2022-09-14 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| US9499532B2 (en) * | 2014-02-07 | 2016-11-22 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| CN105622511B (zh) * | 2014-11-03 | 2018-01-23 | 北京瑞都医药科技有限公司 | 一种减肥药物及其制备方法 |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| EP3818050B1 (en) | 2018-07-05 | 2023-05-31 | Bayer Aktiengesellschaft | Substituted thiophenecarboxamides and analogues as antibacterials agents |
| CN111196772B (zh) * | 2018-11-16 | 2022-09-30 | 沈阳化工研究院有限公司 | 一种芳酰氨基异丁酰衍生物及其应用 |
| CA3165263A1 (en) | 2019-12-20 | 2021-06-24 | Bayer Aktiengesellschaft | Thienyloxazolones and analogues |
| ES3068139T3 (es) | 2020-11-06 | 2026-05-27 | Boehringer Ingelheim Int | Derivados de 2¿[tiofen¿2-il)formamido]¿N¿(fenil)¿2-metilpropanamida y su uso como medicamento |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| OA12323A (en) * | 2000-03-21 | 2006-05-15 | Smithkline Beecham Corp | Protease inhibitors. |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| EP1401453A4 (en) | 2001-05-17 | 2005-04-06 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| AR042064A1 (es) | 2002-11-19 | 2005-06-08 | Takeda Pharmaceutical | Compuestos de amina con actividad inhibidora de la union al receptor de somastotina |
| JP2004300133A (ja) * | 2002-11-19 | 2004-10-28 | Takeda Chem Ind Ltd | アミン誘導体 |
| DE10254336A1 (de) * | 2002-11-21 | 2004-06-03 | Merck Patent Gmbh | Carbonsäureamide |
| US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
| WO2005111013A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| KR20070012552A (ko) * | 2004-05-13 | 2007-01-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 치환된 티오펜카복스아미드, 이의 제조방법 및약제로서의 이의 용도 |
| WO2005111014A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| DE102004047840A1 (de) * | 2004-09-29 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20081834A1 (es) | 2006-12-31 | 2009-01-16 | Boehringer Ingelheim Int | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos |
-
2006
- 2006-06-27 PE PE2006000745A patent/PE20070171A1/es not_active Application Discontinuation
- 2006-06-28 NZ NZ565440A patent/NZ565440A/en not_active IP Right Cessation
- 2006-06-28 DE DE502006008392T patent/DE502006008392D1/de not_active Expired - Lifetime
- 2006-06-28 BR BRPI0612580A patent/BRPI0612580A8/pt not_active Application Discontinuation
- 2006-06-28 EA EA200702620A patent/EA015188B1/ru not_active IP Right Cessation
- 2006-06-28 RS RS20110015A patent/RS51572B/sr unknown
- 2006-06-28 AU AU2006265216A patent/AU2006265216B2/en not_active Ceased
- 2006-06-28 WO PCT/EP2006/063611 patent/WO2007003536A1/de not_active Ceased
- 2006-06-28 HR HR20110044T patent/HRP20110044T2/hr unknown
- 2006-06-28 SG SG201004677-9A patent/SG163540A1/en unknown
- 2006-06-28 ES ES06763910T patent/ES2357029T3/es not_active Expired - Lifetime
- 2006-06-28 US US11/993,426 patent/US20100216769A1/en not_active Abandoned
- 2006-06-28 KR KR1020087002478A patent/KR101321722B1/ko not_active Expired - Fee Related
- 2006-06-28 EP EP06763910A patent/EP1899330B9/de not_active Expired - Lifetime
- 2006-06-28 MY MYPI20063092A patent/MY145883A/en unknown
- 2006-06-28 MX MX2007016253A patent/MX2007016253A/es active IP Right Grant
- 2006-06-28 AT AT06763910T patent/ATE489381T1/de active
- 2006-06-28 PT PT06763910T patent/PT1899330E/pt unknown
- 2006-06-28 PL PL06763910T patent/PL1899330T3/pl unknown
- 2006-06-28 UA UAA200800769A patent/UA94910C2/ru unknown
- 2006-06-28 DK DK06763910.4T patent/DK1899330T3/da active
- 2006-06-28 CA CA2613059A patent/CA2613059C/en not_active Expired - Fee Related
- 2006-06-28 SI SI200630915T patent/SI1899330T1/sl unknown
- 2006-06-28 CN CN2006800242678A patent/CN101213195B/zh not_active Expired - Fee Related
- 2006-06-28 JP JP2008517518A patent/JP4768016B2/ja not_active Expired - Fee Related
- 2006-06-29 TW TW095123603A patent/TWI392495B/zh not_active IP Right Cessation
- 2006-06-30 AR ARP060102825A patent/AR054627A1/es active IP Right Grant
-
2007
- 2007-10-05 ZA ZA200708525A patent/ZA200708525B/xx unknown
- 2007-10-11 NO NO20075186A patent/NO340670B1/no not_active IP Right Cessation
- 2007-12-20 IL IL188323A patent/IL188323A/en not_active IP Right Cessation
- 2007-12-27 EC EC2007008058A patent/ECSP078058A/es unknown
-
2011
- 2011-02-16 CY CY20111100202T patent/CY1111627T1/el unknown
-
2013
- 2013-03-05 US US13/785,176 patent/US9062034B2/en not_active Expired - Lifetime
-
2015
- 2015-05-19 US US14/716,227 patent/US9676781B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30979A1 (es) | Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos | |
| ECSP088824A (es) | Prolinamidas sustituidas, su preparación y su uso como medicamentos | |
| ECSP066898A (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento | |
| UY28773A1 (es) | Nuevas amidas de ácidos carboxílicos, su preparación y su uso como medicamentos. | |
| UY28859A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento | |
| ECSP12012161A (es) | Compuestos en calidad de antagonistas de Bradiquinina-b1 | |
| UY30314A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
| ECSP10010599A (es) | Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk) | |
| CR11861A (es) | Compuestos organicos | |
| UY28040A1 (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos. | |
| GT200400146A (es) | Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso | |
| ECSP10010654A (es) | Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk) | |
| ECSP109978A (es) | Nuevos compuestos | |
| BRPI0606112A2 (pt) | 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica | |
| ECSP10010105A (es) | Antagonistas de cgrp | |
| UY28848A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos | |
| UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
| TW200738692A (en) | New substituted glycinamides, process for their manufacture and use thereof as medicaments | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| CR11273A (es) | Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica | |
| CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| UY31286A1 (es) | Antagonistas de receptores de bradiquinina b1. proceso de preparación y aplicaciones. | |
| DOP2007000121A (es) | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso | |
| UY28879A1 (es) | Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos | |
| UY28795A1 (es) | Nuevas 5-acilindolinonas con contenido en cicloalquilo, su preparación y sus uso como medicamento |